Latest Distribution Partnerships News

Xenitra Limited has swiftly moved from concept to commercial traction, generating over $100,000 in sales within the first week of launching EZZ Life Sciences products on its blockchain-based OPAL token ecosystem.

Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.

OMG Group has appointed Food & Dairy Co as the first official distributor of its new matcha brands, opening access to over 2,000 cafes and restaurants in NSW and Queensland. This move marks a key step in OMG’s strategy to expand its health-focused beverage portfolio.

OMG Group has launched two new matcha brands targeting both premium and mass-market consumers, supported by a five-year exclusive supply agreement for ceremonial-grade Japanese matcha. This move positions OMG to capitalise on the booming global matcha market through a vertically integrated strategy.

Rhythm Biosciences has inked a pivotal distribution agreement with UK-based Digistain Limited to introduce its geneType™ genetic test portfolio in Southeast Asia, starting with the Philippines. This marks Rhythm’s first commercial foothold in the region, setting the stage for broader expansion.

De.mem Limited reported a 20% increase in revenue to $29.9 million for FY2025, alongside a reduced net loss and its first full-year positive adjusted EBITDA. The company also completed the acquisition of Core Chemicals, expanding its specialty chemicals footprint in the gold mining sector.

Volt Group Limited reported an 8% revenue decline and a 66% drop in profit for 2025, while advancing its growth strategy through a major acquisition and share consolidation.

TZ Limited reported a $1.92 million loss for the half-year ending December 2025, with revenues of $5.4 million impacted by delayed US projects and integration challenges from its Keyvision acquisition. The company is banking on large tenders and expanding Microsoft data centre sales to drive recovery.

Sprintex Limited reported a 162% surge in revenue to A$2.7 million for the half-year ending December 2025, driven by a landmark €15.6 million European contract. Despite this, the company posted a net loss of A$1.7 million, an improvement from the prior year, while raising $3.6 million to support global expansion.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Biome Australia Limited has reported a robust half-year performance, with revenues climbing nearly 40% and net profit more than doubling, driven by strong product momentum and strategic investments.

Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.